ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The largest US chemical maker is delaying a Canadian project and planning to idle plants in Europe
The biennial Conference of the Parties to the Basel, Rotterdam, and Stockholm conventions will consider banning the controversial pesticide and two other toxic compounds
German firm boosts its US position and adds oncology drugs and pipeline to health-care business
Trustworthy science coverage is more than facts, think about how a news outlet writes its stories and its promises to you
Hosts David and Gina enter the quantum realm to trace the evolution of this futuristic technology
Chemical educator and Compound Interest blogger Andy Brunning explores the materials science of permanent magnets
Students from all fields lose out on tens of millions of dollars in career-boosting funds this year
The protective garments are not only uncomfortable but can pose a danger to researchers
Science organizations are exploring new avenues and navigating multiple obstacles as they confront the Trump administration’s unprecedented actions
Despite the termination, the 2 companies plan to forge ahead without HHS grants
Drugmakers sort through many modalities to find the best match for their target proteins
The US won’t be party to the global agreement that will allow for rapid sharing of pandemic-related information, pathogen samples, and genetic sequences
The first scaled-up synthesis of this 9-sugar ring could expand its applications